Tolerability and Safety of Subcutaneous Administration of Two Doses of AFFITOPE® PD01A in Early Parkinson's Disease

Phase 1

Completed

• Conditions: Parkinson's Disease
• Interventions: Biological: AFFITOPE® PD01A; Other: Control

• Registration Number: NCT01568099
• Lead Sponsor: Affiris AG

Brief Summary

This is a phase I study to assess the tolerability and safety of 4 injections of two different doses of AFFITOPE® PD01A formulated with an adjuvant to patients with early Parkinson's disease in male and female patients aged 45 to 65 years (or age between 40 and 45 years if there is no evidence for genetic forms of the disease and the diagnosis of idiopathic Parkinson's disease was confirmed, after approval by Sponsor). One study site in Vienna (Austria) will be involved. Each patient's participation will last 1 year.

In addition, up to 8 patients will be offered participation within an untreated control group.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-02
• Study First Submitted: 2012-03-16
• Study First Submitted QC: 2012-03-29
• Study First Posted: 2012-04-02
• Primary Completion: 2014-05
• Study Completion: 2014-05
• Status Verified: 2015-08
• Last Update Submitted: 2015-08-14
• Last Update Posted: 2015-08-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 32

Inclusion Criteria

• Informed consent capability
• Early PD (≤ 4 years), Hoehn&Yahr Stages I/II and fulfill the UK Parkinson's Disease Society Brain Bank Criteria
• Brain magnetic resonance imaging (MRI) scan and DAT-SPECT scan are consistent with the diagnosis of PD
• Age between 45 and 65 years or age between 40 and 45 years if there is no evidence for genetic forms of the disease and the diagnosis of idiopathic PD was confirmed, after approval by Sponsor
• Caregiver able to attend all visits with patient
• Stable doses of medications (levodopa (+/- benserazide, carbidopa), COMT inhibitors (entacapone, tolcapone), non-ergot dopamine agonists (pramipexol, ropinirol, rotigotine), the MAO-B inhibitor rasagiline and amantadine are allowed)

Exclusion Criteria

• Women of childbearing potential without birth control or pregnant women
• Participation in another clinical trial
• Autoimmune disease or allergy to components of the vaccine
• Contraindications for MRI, DAT-SPECT, colonoscopy including biopsy or lumbar puncture
• Dementia
• History of cancer (Exceptions: basal cell carcinoma, intraepithelial cervical neoplasia)
• Active infectious disease
• Immunodeficiency
• Significant systemic illness or psychiatric illness
• Parkinson-like disease secondary to drug therapy side effects
• Parkinson-plus syndromes
• Heredodegenerative disorders
• Alcoholism or substance abuse
• Prior treatment with experimental immunotherapeutics for PD including IVIG, with immunosuppressive drugs or treatment with deep brain stimulation
• Venous status rendering it impossible to place an i.v. access

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
B: AFFITOPE® PD01A + Adjuvant	AFFITOPE® PD01A	4 injections of 75µg AFFITOPE® PD01A/ adjuvanted, once every 4 weeks
Control	Control	Untreated control group
A: AFFITOPE® PD01A + Adjuvant	AFFITOPE® PD01A	4 injections of 15µg AFFITOPE® PD01A/ adjuvanted, once every 4 weeks

Primary Outcome Measures

Name	Time	Method
Tolerability/Safety	12 month	* Occurrence of any AE (including a clinical grading scale of AEs according to NCI-CTCAE Version 4.02 (2009) for assessments of AEs + toxicity and including a grading of local injection site reactions according to the FDA Guidance for Industry: Toxicity Scale for Healthy Adult and Adolescents Patients Enrolled in Preventive Vaccine Clinical Trials (2007)); * Occurrence of any SAE; * Withdrawal criteria (number of patients who withdraw due to AEs/ reason for withdrawal)

Secondary Outcome Measures

Name	Time	Method
Immunological	12 month	- Titer of vaccination induced antibodies directed towards vaccine components, alpha- and beta synuclein
Clinical Activity	12 month	* Change in motor symptoms (MDS-UPDRS III); * Change in non-motor PD symptoms (e.g.; MDS-UPDRS Ia, II, PDQ39, cognition); * Change in biological and radiological markers (e.g. CSF alpha synuclein levels)

Trial Locations

Locations (1)

Studienzentrum der PROSENEX, AmbulatoriumbetriebsgesmbH an der Confraternität-Privatklinik Josefstadt, Skodagasse 32, 1080 Vienna; 🇦🇹 Vienna, Austria